AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMAB
  4. [6-K] I-MAB American Current Report (Foreign Issuer)

[6-K] I-MAB American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
雼れ潓 韰嶌姢韸鸽ゼ 雼れ嫓 鞛戩劚頃橃劯鞖�:
R茅茅crivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
雼れ潓 韰嶌姢韸鸽ゼ 雼れ嫓 鞛戩劚頃橃劯鞖�:
R茅茅crivez le texte suivant :
Schreibe den folgenden Text um:

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

 

 

Commission File Number: 001-39173

 

 

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

 

 

99.1

 

Press Release - I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

 

99.2

 

Presentation - A Phase 1b dose escalation study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma

 

99.3

 

Investor Presentation - July 2, 2025

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

I-MAB

 

 

 

By

:

/s/ Joseph Skelton

 

Name

:

Joseph Skelton

 

Title

:

Chief Financial Officer

 

Date: July 2, 2025

Source:

FAQ

What information is available?

This document appears to contain limited substantive content.
Stock IMAB logo
I-Mab

NASDAQ:IMAB

IMAB Rankings

#7106 Ranked by Market Cap
N/A Ranked by Dividends

IMAB Latest News

Jul 2, 2025
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Jun 30, 2025
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
Jun 26, 2025
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Jun 18, 2025
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
Jun 12, 2025
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

IMAB Latest SEC Filings

Jun 26, 2025
[6-K] I-MAB American Current Report (Foreign Issuer)

IMAB Stock Data

227.02M
57.94M
11.16%
33.33%
1.09%
Biotechnology
Healthcare
United States
Rockville